Insurer accuses Janssen of sham lawsuits to stop cancer generic

25-04-2019

Insurer accuses Janssen of sham lawsuits to stop cancer generic

Ken Wolter / Shutterstock.com

A US health insurance provider is suing a subsidiary of Johnson & Johnson for filing “sham” patent litigation in a bid to stop generic forms of a prostate cancer treatment from entering the market.


Janssen Biotech, Zytiga, prostate cancer, Blue Cross Blue Shield, Johnson & Johnson, generics

LSIPR